Marin Xavier

Immune checkpoint inhibition for advanced cutaneous squamous cell carcinoma in patients with concomitant chronic lymphocytic leukemia: Integrated single-center and national Cosmos analyses.

Luke M. Shenton, Jacob New, Natalia M. Orendain, SAMANTHA R. BAGSIC et autres

e21565 Background: Patients with chronic lymphocytic leukemia (CLL) have immune dysregulation and increased risk of aggressive cutaneous squamous cell carcinoma (cuSCC), yet prospective ICI trials largely excluded this population. We combined detailed single-center chart review with a national real-world dataset to characterize …

us (code pays fourni par la source)

Real-world patient management practices in responders to venetoclax for newly diagnosed acute myeloid leukemia.

Ofir Wolach, Pinkal Desai, Evan Chris Chen, Joshua F. Zeidner et autres

6527 Background: Venetoclax (VEN) is approved for adult patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) in combination with hypomethylating agents (HMAs) or low dose cytarabine. This abstract describes real-world pt management practices among pts with ND AML who respond …

il, us, ca (code pays fourni par la source)

First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma

Ethan Canty, Lori Broderick, Daniel P. Flaherty, Marin Xavier et autres

Chimeric antigen receptor T-cell (CAR T-cell) therapy has significantly advanced cancer treatments and remission rates; however, questions exist regarding the impacts on both fertility and immune effects on infants born to mothers who have undergone CAR T-cell therapy. There are no known …

us (code pays fourni par la source)

Immunotherapy at the end of life.

Gagandeep Kaur, Catherine Weir, Terrence Sun, Havi Rosen et autres

188 Background: It is well established in the literature that cancer treatment administered at the end of life (EOL) does not improve either quality of life or survival rates. Patients undergoing systemic cancer treatments at near the EOL often have reduced access …

us (code pays fourni par la source)

The use of ibrutinib for the management of paraneoplastic bullous pemphigoid associated with monoclonal B-lymphocytosis: A case report and brief literature review

Vy Xuan Pham, Aleksandr Itkin, Marin Xavier, Erik Gilbertson

us (code pays fourni par la source)

Patient Portal Utilization Improves Outcomes in Patients with Multiple Myeloma

Elisa Quiroz, Aren Ebrahimi, Alberto Godinez, Leah Puglisi et autres

A growing body of literature has demonstrated improved quality of life in cancer patients who utilize web-based patient portals; however, no studies have investigated their impact on objective clinical measures. The study aimed to evaluate the impact of patient portal utilization on …

us (code pays fourni par la source)

Racial, ethnic, and regional influences on national patterns of mammographic screening for breast cancer.

Thomas A. Buchholz, Emily C. Soriano, Shane Mesko, Marin Xavier et autres

1600 Background: Racial, ethnic, and geographic factors can affect disparities in medical care. Mammographic screening has been demonstrated to reduce the risk of breast cancer death for appropriate subsets of women and accordingly is an accepted standard recommendation. Herein, we studied the …

us (code pays fourni par la source)

A case of indolent systemic mastocytosis responding to treatment with Avapritinib

Terrence Sun, Marin Xavier

Low dose Avapritinib is a new medication that is a potential treatment option not just for advanced systemic mastocytosis, but also for the indolent form.

us (code pays fourni par la source)

Long COVID-19 Infections and Organizing Pneumonia in a Series of Patients with Indolent Lymphoma Treated with Rituximab

David G. Savage, Marin Xavier, James R. Mason, Jacqueline Chang et autres

Background: Patients with hematologic malignancies have an increased risk of complications and mortality from COVID-19 (SARS-CoV-2). These patients are often more susceptible to protracted COVID-19 infections (e.g., long COVID-19). In addition, patients treated with the CD20-targeted immunotherapy rituximab in B-cell lymphomas are …

us (code pays fourni par la source)

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Pinkal Desai, Jacqueline S. Garcia, Joshua F. Zeidner, Sameem Abedin et autres

Introduction: The BCL-2 inhibitor VEN is approved in combination with hypomethylating agents or low-dose cytarabine for adults with ND AML. The ARC Initiative is a multicenter chart review study of adult pts with AML. This abstract presents real-world clinical outcomes and hospitalizations …

us, il, ca (code pays fourni par la source)

A Case of Indolent Systemic Mastocytosis Responding to Treatment with Avapritinib

Terrence Sun, Marin Xavier

Introduction: Systemic Mastocytosis (SM) is a rare disorder in which mast cells pathologically accumulate within tissue. The mast cells can be limited to the skin, or they can be systemic and involve extracutaneous tissues. One subtype of systemic mastocytosis (SM) is called …

us (code pays fourni par la source)

177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting.

Jessica K. Sassic, Sadaf Farasat, David J. Hermel, Darren Sigal et autres

e16249 Background: Neuroendocrine tumors (NET) have an incidence of around 6.98/100k per year. Long-acting somatostatin receptor agonists (SSA) are first-line therapy for non-resectable disease. In January 2018, the United States FDA approved 177Lu-DOTATATE (PRRT) for second-line therapy in patients with somatostatin receptor-positive …

us (code pays fourni par la source)